Udhay Krishnan

Udhay Krishnan

Auto-generated profile, based on publicly available information

Udhay Krishnan

Weill Cornell Cardiovascular Outcomes Research Group (CORG), Weill Cornell Medical College, New York, NY 10021, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The American Journal of Medicine
Verified
Journal Article
Closed access
UKUdhay Krishnan
Udhay Krishnan
JBJosef A. Brejt
Josef A. Brejt
JSJoshua Schulman-Marcus
Joshua Schulman-Marcus
RSRajesh V. Swaminathan
Rajesh V. Swaminathan
DFDmitriy N. Feldman
Dmitriy N. Feldman
LKLuke K. Kim
Luke K. Kim

1 December 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JWJoseph I. Wang
Joseph I. Wang
DLDaniel Y. Lu
Daniel Y. Lu
MHMhs
Mhs
DFDmitriy N. Feldman
Dmitriy N. Feldman
SMStephen A. McCullough
Stephen A. McCullough
UKUdhay Krishnan
Udhay Krishnan
Background: Cardiogenic shock (CS) is a complex syndrome associated with high morbidity and mortality. In recent years, many US hospitals have formed multidisciplinary shock teams capable of rapid diagnosis and triage. Because of preexisting collaborative systems of care, hospitals with left ventricular assist device (LVAD) programs may also represent “centers of excellence” for CS care. However, the outcomes of patients with CS at LVAD centers have not been previously evaluated. Methods and Results: Patients with CS were identified in the 2012 to 2014 National Inpatient Sample. Clinical characteristics, revascularization rates, and use of mechanical circulatory support were analyzed in LVAD versus non‐LVAD centers. The association between hospital type and in‐hospital mortality was examined using multivariable logistic regression models. Of 272 075 hospitalizations, 26.0% were in LVAD centers. CS attributable to causes other than acute myocardial infarction represented most cases. In‐hospital mortality was lower in LVAD centers (38.9% versus 43.3%; P <0.001). In multivariable analysis, the odds of mortality remained significantly lower for hospitalizations in LVAD centers (odds ratio, 0.89; P <0.001). In patients with CS secondary to acute myocardial infarction, revascularization rates were similar between LVAD and non‐LVAD centers. The use of intra‐aortic balloon pump (18.7% versus 18.8%) and Impella/TandemHeart (2.6% versus 1.9%) was similar between hospital types, whereas extracorporeal membrane oxygenation was used more frequently in LVAD centers (4.3% versus 0.2%; P <0.001). Conclusions: Risk‐adjusted mortality was lower in patients with CS who were hospitalized at LVAD centers. These centers likely represent specialized, shock team capable institutions across the country that may be best suited to manage patients with CS.

20 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SJSun-Joo Jang
Sun-Joo Jang
IYIlhwan Yeo
Ilhwan Yeo
CJChanel Jonas
Chanel Jonas
PGParag Goyal
Parag Goyal
JCJim W. Cheung
Jim W. Cheung
LKLuke K. Kim
Luke K. Kim
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.

1 March 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
DLDaniel Lu
Daniel Lu
JKJaya Kanduri
Jaya Kanduri
IYIlhwan Yeo
Ilhwan Yeo
PGParag Goyal
Parag Goyal
UKUdhay Krishnan
Udhay Krishnan
LKLuke K. Kim
Luke K. Kim
BACKGROUND: Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes. METHODS: HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, and mechanical ventilation). Multivariable logistic regression was performed to adjust for the presence of HF decompensations and significant clinical variables during univariate analysis. RESULTS: A total of 2 331 690 hospitalizations (81.2%) were admissions to non-ATCs (94.5% of centers), 525 037 (18.3%) were admissions to ATCs (5.5% of centers), and 15 541 (0.5%) were transferred to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths of stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, P <0.001) and transferred (11.2%, P <0.001) patients. However, multivariable-adjusted mortality was significantly lower at ATCs, both for directly admitted (odds ratio, 0.82 [95% CI, 0.78–0.87]; P <0.001) and transferred (odds ratio, 0.66 [95% CI, 0.57–0.78]; P <0.001) patients. For severe HF admissions, unadjusted mortality was 37.2% at non-ATCs and was lower at ATCs, both for directly admitted (25.3%, P <0.001) and transferred (25.2%, P <0.001) patients, with similarly lower multivariable-adjusted mortality. CONCLUSIONS: Patients with HF treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality.

10 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
DLDaniel Lu
Daniel Lu
JKJaya Kanduri
Jaya Kanduri
IYIlhwan Yeo
Ilhwan Yeo
PGParag Goyal
Parag Goyal
UKUdhay Krishnan
Udhay Krishnan
LKLuke K Kim
Luke K Kim
Background Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data is lacking on decompensated heart failure (HF) admissions and transfers, and the impact of advanced therapy centers (ATCs) on outcomes. Methods HF hospitalizations were obtained from the Nationwide Readmissions Database 2016-2019. Centers performing at least one heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among three cohorts: admissions to non-ATCs, admissions to ATCs, transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, mechanical ventilation). Results 2,331,690 hospitalizations were admissions to non-ATCs (94.5% of centers), 525,037 were admissions to ATCs (5.5% of centers), and 15,541 were transfers to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, p<0.01) and transferred (11.2%, p<0.01) patients. However, multivariable adjusted mortality was significantly lower at ATCs, both for directly admitted (OR 0.82, p<0.01) and transferred (OR 0.66, p<0.01) patients. For severe HF admissions, unadjusted mortality was 37.2% at non-ATCs and was lower at ATCs, both for directly admitted (25.3%, p<0.01) and transferred (25.2%, p<0.01) patients, with similarly lower multivariable adjusted mortality. Conclusions HF patients treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality. Clinical Perspective Contemporary data is lacking on admissions and transfers for decompensated heart failure (HF) and the impact of advanced therapy centers (ATCs) on outcomes. Our findings show that decompensated HF patients treated at ATCs had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. While unadjusted mortality was higher at ATCs, multivariable adjusted mortality was significantly lower at ATCs, both for directly admitted and transferred patients. Our findings will hopefully prompt earlier recognition and referral of patients to ATCs, emphasize the need for increased numbers of ATCs, and spark further research into the decision-making process for referral to ATCs.

16 March 2019
Verified
Book Chapter
Closed access
PDF file
UKUdhay Krishnan
Udhay Krishnan
EHEvelyn M. Horn
Evelyn M. Horn